Does prostacyclin enhance the selective pulmonary vasodilator effect of oxygen in children with congenital heart disease?
- 1 July 1986
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 74 (1) , 135-144
- https://doi.org/10.1161/01.cir.74.1.135
Abstract
We have obtained dose-response curves for the effects of prostacyclin on the pulmonary and systemic circulations in 20 children (median age 3 years) with pulmonary hypertension complicating congenital heart disease. Results were obtained with the children breathing both air and 100% oxygen. Under both sets of conditions, remote respiratory mass spectrometry was used to measure oxygen consumption and hence cardiac output by the direct Fick principle. When the subjects breathed air, prostacyclin caused a dose-dependent fall in pulmonary vascular resistance (measured in mm Hg . liter-1 . min . m2) (11.12 to 8.07, standard error of difference [SED] = 0.5, p less than .01). The level of the pulmonary vascular resistance when the subjects breathed air during the infusion of 20 ng/kg/min prostacyclin was not significantly different from that found when they breathed 100% oxygen and did not receive the drug (8.67 vs 8.93, SED = 0.55, p = NS). When infused while the subjects breathed 100% oxygen, prostacyclin caused additional dose-dependent pulmonary vasodilation (pulmonary vascular resistance 8.93 to 7.23, SED = 0.3, p less than .01). Unlike 100% oxygen, prostacyclin was not selective, and caused tachycardia and systemic hypotension at the higher doses. These results suggest that in children with congenital heart disease 100% oxygen does not maximally vasodilate the pulmonary circulation, and further pulmonary vasodilatation can be obtained with a blood-borne agent.This publication has 31 references indexed in Scilit:
- The use of oxygen and prostacyclin as pulmonary vasodilators in congenital heart diseaseInternational Journal of Cardiology, 1985
- Pulmonary Oxygen ToxicityNew England Journal of Medicine, 1983
- Quantitative differences in the hemodynamic effects of captopril and nitroprusside in severe chronic heart failureThe American Journal of Cardiology, 1983
- Deleterious Effects of Hydralazine in Patients with Pulmonary HypertensionNew England Journal of Medicine, 1982
- The role of hydralazine therapy for pulmonary arterial hypertension of unknown cause.Circulation, 1982
- Inhibition of Hypoxic Pulmonary Vasoconstriction by NifedipineNew England Journal of Medicine, 1981
- The uses of long sampling probes in respiratory mass spectrometryRespiration Physiology, 1979
- The measurement of metabolic gas exchange and minute volume by mass spectrometry aloneRespiration Physiology, 1979
- Neonatal hypoxia and pulmonary vasospasm: Response to tolazolineThe Journal of Pediatrics, 1976
- Effects of tolazoline hydrochloride (priscoline) on circulatory dynamics of patients with pulmonary hypertensionAmerican Heart Journal, 1958